Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.
The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...
Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...